Abstract 1686P
Background
As global cancer cases increase exponentially, the number of caregivers subsequently increases to support patients. Despite being indispensable, the available resource was reserved mainly for patients, undermining the importance of caregivers who also share the struggle and burden. The chronic amount of stress and responsibility that caregivers face leads to impairment of quality of life (QOL). Further, most research that assesses the QOL is mainly conducted in the developed countries with robust palliative care. This comparative study aims to map and explore the status quo of QOL levels from caregivers of cancer patients in Asia. In addition, to investigate the correlation of QOL impairments in caregivers with sociodemographic factors.
Methods
A comprehensive systematic review of the literature was performed through databases with the keywords “cancer”, “caregiver”,” quality of life”, and “Asia” spans from 2004-2024. 371 articles that satisfy eligible criteria were retrieved. A total of 1271 family caregivers for cancer patients who had taken outpatient treatment, finished sociodemographic, and the Caregiver Quality of Life Index-Cancer (CQOLC) survey were included. Gathered CQOLC total scores from 12 countries including Indonesia, Singapore, Malaysia, Turkey, Iran, Jordanian, India, South Korea, China, Taiwan, Japan, and Saudi Arabia dataset, were compared and analyzed for their correlation with sociodemographic factors.
Results
Different distributions of total scores of CQOLC in 12 Asia countries observed with higher CQOLC total scores were scored within the developed countries with mature palliative care systems. Further, varying caregiver determinants including different sociodemographic characteristics could produce impaired QOL such as male gender, parental relationships, certain ethnicity, and late-stage cancer.
Conclusions
Despite sharing cultural context and family-based caregivers, uneven QOL distribution was observed across Asian countries. This study also highlights the potential areas to be improved. Additionally, acknowledging the diversity of values, culture, and socio-demographics significantly helps in creating more optimal interventions to support caregivers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11